Name

R-DHAX

Alternate names

None

Primary Site

None

Histology

Lymphoma

Radiation

None

Remarks

None

Drugs for R-DHAX

Name

Alternate Names

Anti-CD20 monoclonal antibodies
C2B8 monoclonal antibody
IDEC-C2B8
MabThera
Monoclonal antibody IDEC-C2B8
Rituxan

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Cytostatic monoclonal antibody

NSC Number

687451

Primary Site

Leukemia
NHL

Histology

None

Remarks

December 2, 2021 The FDA approved rituximab (Rituxan, Genentech, Inc.) in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.

FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.

FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.

FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.

FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieved response to rituximab in combination with chemotherapy.

June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.


.

Coding

This drug should be coded

Name

Alternate Names

Aeroseb-Dex
AK-Dex
AK-Trol
Baldex
Component of Deronil
Component of Dexacidin
Component of Maxitrol
Dalalone
Decaderm
Decadrol
Decadron Tablets
Decajet
Decameth
Decasone
Decaspray
Deenar
Dex-4
Dexacen
Dexacidin
Dexacort Phosphate
Dexameth
Dexasone
Dexasporin
Dexone
Dexsone
Dezone
Gammacorten
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Infectrol Sterile
Maxidex
Maxitrol
Miral
Mymethasone
Neo-Dexameth
Neodecadron
Neodexair
Ocu-Trol
Oradexon
PMS-Dexamethasone Sodium Phosphate
SK-Dexamethasone
Sofracort
Sofradex
Solurex
Spersadex
Sterile Dexamethasone Acetate
Tobradex
Turbinare Decaron Phosphate

Abbreviations

DECA
DM
DSM

Category

Ancillary Agent
Hormones and hormonal mechanisms

Subcategory

Glucocorticoid. Probably not cancer directed--verify with attending MD.

NSC Number

345211

Primary Site

None

Histology

None

Remarks

NOTE* Dexamethasone may be coded as either an ancillary drug or hormone. Review chart to determine if given for supportive care or as hormonal therapy. IMPORTANT INFORMATION: dexamethasone is frequently included in treatment regimens, however, this does not indicate it should be coded as hormone therapy. Be sure to review the regimen tab in "Search Database" for additional coding information.

A long-acting corticosteroid (glucocorticoid). In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy. 25 times as potent as cortisol; used topically as an anti-inflammatory and administered orally in replacement therapy for adrenal insufficiency, as an anti-inflammatory and immunosuppressant in a wide variety of disorders, and as an antiemetic in cancer chemotherapy. Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for lymphoid leukemia, lymphoma and multiple myeloma.

Coding

Please see remarks for additional information

Name

Alternate Names

AC-1075
Alexan
Ara-cytidine
Arabinocytidine
Arabinosylcytosine
Beta-Arabinosylcytosine
Cytarabin
Cytarabine
Cytarabinoside
Cytosar
Cytosar-U
Cytosine Arabinoside
Cytosine arabinoside hydrochloride
Spongocytidine HCL
Tarabine
Tarabine PFS
U-19920
U-19920A
WR-28453

Abbreviations

ara-C
CA
HDA
HDARA-C

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

063878
63878

Primary Site

ALL
AML
CML
head and neck
Hodgkin's disease
leukemia
Meningeal leukemia
NHL

Histology

None

Remarks

Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)

Coding

This drug should be coded

Name

Alternate Names

1-OHP
1670 RBl Eloxatin
Eloxatin
L-OHP
Oxalatoplatin
Oxalatoplatinum
PR-54780
RP-54780
Transplatin

Abbreviations

None

Category

Chemotherapy

Subcategory

Platinum analog

NSC Number

266046

Primary Site

Colorectal
gastro-esophageal cancers, metastatic
liver
ovarian
pancreatic cancer

Histology

None

Remarks

A platinum-containing antineoplastic that is usually given in combiantion with 5-FU.

Coding

This drug should be coded
Glossary